{
    "clinical_study": {
        "@rank": "119375", 
        "arm_group": {
            "arm_group_label": "RoActemra/Actemra Arm", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, single-arm study will evaluate the efficacy and safety of RoActemra/Actemra\n      (tocilizumab) in patients with active moderate to severe rheumatoid arthritis. Patients will\n      receive a subcutaneous dose of RoActemra/Actemra 162 mg once weekly. The anticipated time on\n      study treatment is 24 weeks."
        }, 
        "brief_title": "An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients at least 18 years of age\n\n          -  Patients with a diagnosis of active moderate to severe rheumatoid arthritis (RA)\n\n          -  Oral corticosteroids and nonsteroidal anti-inflammatory are permitted if on a stable\n             dose regimen for >/= 4 weeks prior baseline\n\n          -  Permitted non-biologic DMARDs used alone or in combination are allowed if at a stable\n             dose for at least 4 weeks prior to baseline\n\n          -  Receiving treatment on an outpatient basis, not including RoActemra/Actemra\n\n          -  Females of childbearing potential and males with female partners of childbearing\n             potential may participate in this study only if using a reliable means of\n             contraception for at least 5 months following the last dose RoActemra/Actemra\n\n          -  Previous or current treatment with methotrexate with an inadequate response to\n             methotrexate, intolerance to methotrexate or treatment with methotrexate was\n             considered as inappropriate\n\n          -  Evidence of i or more erosions in hands or feet assessed by X-ray attribute to RA or\n             MRI of wrist of MCP joints of dominant hand\n\n        Exclusion Criteria:\n\n          -  Major surgery (including joint surgery) within 8 weeks prior to screening or planned\n             major surgery within 6 months following baseline\n\n          -  Rheumatic autoimmune disease other than rheumatoid arthritis\n\n          -  Functional Class IV as defined by the ACR Classification of Functional Status in\n             Rheumatoid Arthritis\n\n          -  Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of\n             16\n\n          -  Prior history of current inflammatory joint disease other than RA\n\n          -  Exposure to RoActemra/Actemra at any time prior to baseline\n\n          -  Treatment with any investigational agent within 4 weeks (or five half-lives of the\n             investigational drug, whichever is longer) of screening\n\n          -  Previous treatment with any cell-depleting therapies\n\n          -  Treatment with IV gamma globulin, plasmapheresis within 6 months of baseline\n\n          -  Intraarticular (IA) or parenteral corticosteroids within 4 weeks prior to baseline\n\n          -  Any previous treatment with alkylating agents such as chlorambucil, or with total\n             lymphoid irradiation\n\n          -  Treatment with 2 or more anti-TNFs or any other biologic agent at any time prior to\n             screening\n\n          -  Evidence of serious uncontrolled concomitant disease (e.g., cardiovascular, nervous\n             system, pulmonary)\n\n          -  History of diverticulitis, diverticulosis requiring antibiotic treatment, or chromic\n             ulcerative lower GI disease such as Crohn's disease, ulcerative colitis, or other\n             symptomatic lower GU conditions that might predispose to perforation\n\n          -  Known active current or history of recurrent infections"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01951170", 
            "org_study_id": "ML28703"
        }, 
        "intervention": {
            "arm_group_label": "RoActemra/Actemra Arm", 
            "description": "tocilizumab 162 mg subcutaneously once weekly for 24 weeks", 
            "intervention_name": "Tocilizumab (RoActemra/Actemra)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Camperdown", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2050"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coffs Harbour", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2450"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kogarah", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2217"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Southport", 
                        "country": "Australia", 
                        "state": "Queensland", 
                        "zip": "4215"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Adelaide", 
                        "country": "Australia", 
                        "state": "South Australia", 
                        "zip": "5000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hobart", 
                        "country": "Australia", 
                        "state": "Tasmania", 
                        "zip": "7100"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Geelong", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3220"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ivanhoe", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3079"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malvern East", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3145"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morwell", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3842"
                    }
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Study to Evaluate Non-Progression Of Structural Joint Damage Of Subcutaneous Tocilizumab In Patients With Moderate To Severe Active Rheumatoid Arthritis (Ac-Cute)", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28703 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Australia: Therapeutic Goods Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Absolute change in Genant-modified total Sharp score (mTSS)", 
            "safety_issue": "No", 
            "time_frame": "From screening to Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01951170"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) remission (defined as DAS28<2.6)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 24"
            }, 
            {
                "measure": "Change in American College of Rheumatology (ACR20/50/70) response", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 24"
            }, 
            {
                "measure": "Change in European League Against Rheumatism (EULAR) Response", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 24"
            }, 
            {
                "measure": "Change in Simplified Disease Activity Index (SDAI)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 24"
            }, 
            {
                "measure": "Change in Clinical Disease Activity Index (CDAI)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 24"
            }, 
            {
                "measure": "Change in total tender joint count (TJC)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 24"
            }, 
            {
                "measure": "Change in swollen joint count (SJC)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 24"
            }, 
            {
                "measure": "Change in Patient Reported Outcomes", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 24"
            }, 
            {
                "measure": "Safety: Adverse events", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Safety: Assessment of immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "32 weeks"
            }, 
            {
                "measure": "Absolute change from baseline in rheumatoid arthritis magnetic resonance imaging scoring system (RAMRIS) scoring of erosions, synovitis, cartilage loss and osteitis.", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 24"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}